Dyne Therapeutics, Inc.DYNNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank43
5Y CAGR-49.5%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-49.5%/yr
Long-term compound
Percentile
P43
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 11.80% |
| 2024 | 98.98% |
| 2023 | 11.34% |
| 2022 | -1.79% |
| 2021 | 125.28% |
| 2020 | 357.54% |
| 2019 | 438.88% |
| 2018 | -99.73% |
| 2017 | 17.39% |
| 2016 | 25.78% |